Appropriate leucine-rich α-2 glycoprotein cut-off value for Japanese patients with ulcerative colitis

Table 1 Baseline characteristics of the 30 patients

Parameter	Patients (n = 30)
Age, year, median (IQR)	37 (28-47)
Male/Females, n/n	21/9
Disease duration, year, median (IQR)	1 (0-1)
Actual disease extent, n (%)
Proctitis	3 (10)
Left-sided colitis	7 (23.3)
Total colitis	20 (66.7)
Segmental colitis	0
Laboratory data
LRG, μg/mL, median (IQR)	11.9 (9.8-20.1)
CRP, mg/dL, median (IQR)	0.10 (0.10-0.33)
Medication, n (%)
5-aminosalicylic acid	30 (100)
Immunomodulators	3 (10)
Anti-TNF	2 (6.7)
Ustekinumab	1 (3.3)
Tofacitinib	3 (10)

IQR: Interquartile range; LRG: Leucine-rich α-2 glycoprotein; CRP: C-reactive protein; TNF: Tumor necrosis factor.

Table 2 Associations of variables with leucine-rich α-2 glycoprotein to predict remission

Variable	Cut-off value (μg/mL)	AUC	95%CI	SENS (%)	SPEC (%)	PPV (%)	PLR
PMS 0	12.9	0.951	0.873-1.000	89	91	94	10.6
MES 0	13.4	0.871	0.744-0.998	100	64	68	2.8
UCEIS 0,1	13.4	0.904	0.792-1.000	100	69	73	3.2
Matts grade 1	9.7	0.889	0.755-1.000	100	81	37	5.4
Riley’s score 0,1	13.4	0.739	0.550-0.929	100	46	32	1.8
GHS 0,1	13.4	0.679	0.477-0.880	92	59	63	2.2

LRG: Leucine-rich α-2 glycoprotein; AUC: Area under the curve; CI: Confidence interval; SENS: Sensitivity; SPEC: Specificity; PPV: Positive predictive value; PLR: Positive likelihood ratio; MS: Mayo Score; MES: Mayo Endoscopic Subscore; UCEIS: Ulcerative Colitis Endoscopic Index of Severity; GHS: Geboes Histopathology Score.